Amgen News

Biotechnology company Amgen Inc. said Friday that Rebecca Henderson has been appointed to the board of directors.

Now We Are Waiting For The FDA To Approve The Drug. When Will The Next Action Be? So you know the biotech market is hot right now especially after VNDA's 900% gain overnight.

Biotech giant Amgen Inc. saw its largest single-day stock-price jump in four years after announcing that its experimental bone-strengthening medicine worked better than a potential rival in a study comparing the two drugs in breast cancer patients.

Since 2002, David and Tom Gardner have returned 25.55% while the S&P 500 returned -13.14%. Try Stock Advisor free for 30 days.

Shares of the following companies are having unusual moves in U.S. trading this morning.

Shares of Amgen Inc. jumped in premarket trading Wednesday after the company said its experimental osteoporosis drug denosumab met a key goal of preventing bone injuries in breast-cancer patients during a late-stage study.

Amgen today announced that a pivotal, Phase 3, head-to-head trial evaluating denosumab versus Zometa in the treatment of bone metastases in 2,049 patients with advanced breast cancer met its primary and secondary endpoints and demonstrated superior efficacy compared to Zometa.

Amgen , the world's largest biotechnology company, said today that its lead experimental drug, denosumab, reached all its goals in a clinical trial of more than 2,000 women with breast cancer.

Illinois Attorney General Lisa Madigan says her office has brokered a $7.2 million settlement agreement with two pharmaceutical companies to settle allegations that they inflated the wholesale price index used for setting Medicaid reimbursements.

Global market for Cancer Therapies in US$ Billion. With analysis of specific product segments such as : Chemotherapy, Targeted Therapy, Hormonal Therapy, Immunotherapy.

Rumors that litigation powerhouse Howrey LLP was in talks to absorb intellectual property litigation boutique Day Casebeer Madrid and Batchelder LLP were confirmed Wednesday morning.

Healthcare has dominated the headlines in recent weeks, as President Obama presents his new proposals and the industry recovers from a position where it was perhaps oversold.

Since 2002, David and Tom Gardner have returned 31.77% while the S&P 500 returned -9.90%. Try Stock Advisor free for 30 days.

The latest data on stock repurchases by companies in the S&P 500 shows a severe year-over-year decline, as most companies conserved cash for what many must have thought was an Armageddon in the financial markets and economy.

Since 2002, David and Tom Gardner have returned 30.96% while the S&P 500 returned -10.28%. Try Stock Advisor free for 30 days.

Executives at U.S. companies are taking advantage of the biggest stock-market rally in 71 years to sell their shares at the fastest pace since credit markets started to seize up two years ago.

Bit by bit, the IPO market is picking up steam. And, the latest deal hit the markets today: Medidata .

Europe's got 'em. Now Japan has 'em. When will the U.S. follow suit? We're talking about follow-on biologics, also known as "biosimilars," depending on the country of origin .

Amgen Inc will find out this year if Aranesp helps prevent heart attacks and other cardiac events in kidney patients, but changing the safety-plagued anemia drug's label would be an uphill battle.

Posted Jun 23rd 2009 12:30PM by Tom Johansmeyer Filed under: Insiders , Personal finance The market takes an upward turn, and the insiders head for the exits.